Drugs / OVEMOTIDE
OVEMOTIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00923195 | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00706992 | Jun 2008 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVEMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | (leu27)-melan-a, mart 1 (26-35) | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Elagigiltv | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Gp100:280-288(288v) peptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | MART-1:26-35(27L) peptide | “Patients will be randomized to receive either the gp100:154-162 peptide or the MART-1:26-35(27L) peptide emulsified in incomplete Freund's adjuvant.” NCT00923195 ↗ |
| Known as | Melan-a(aa26-35*a27l)) | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | MPS-21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Ovemotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Action | Activate | “The procedure also uses one of two vaccines-the anti-MART-1 peptide or the anti-gp100 peptide-to stimulate cells in the immune system” NCT00923195 ↗ |
| Modality | Peptide | “MART-1:26-35(27L) peptide vaccine” NCT00706992 ↗ |
| Route | Subcutaneous | “MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC)” NCT00706992 ↗ |